Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App





New Breakthrough Test Detects and Predicts COVID-19 Severity

By LabMedica International staff writers
Posted on 16 Sep 2022

COVID19 is on pace to be the third-leading cause of death for the third straight year. More...

Since 2020, it has trailed only heart disease and cancer, significantly reducing life expectancy. One of the current clinical challenges in treating COVID is the inability to predict whether a person who tests positive will develop a mild, moderate or severe case. Now, a simple, efficient and quick genomic blood test could be a game-changer in identifying patients who may experience a severe course of COVID and to provide decision support for the type of medical treatments that may be helpful.

AMPEL BioSolutions (Charlottesville, VA, USA) has made a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19 in patients while also determining the best treatment options for each specific case. AMPEL's new genomic test, known as CovGENE, can be administered by drawing a patient's blood to quickly ascertain whether a COVID-19 patient will have a mild, moderate, or severe outcome. After a patient tests positive, the CovGENE blood test will help determine the type of treatment and medicine needed in order to reduce the chances of hospitalization or a medical emergency. The company's new approach, through a simple blood test, will ultimately accelerate the means of providing effective treatments to the right people at the right time and potentially stem the serious illness caused by SARS-CoV-2 infection that can lead to lung damage or death.

CovGENE, has been validated by a longitudinal study. In a careful analysis of patients admitted to the intensive care unit, CovGENE demonstrated remarkable precision with a greater than 90% rate of accuracy. CovGENE is becoming available at a crucial time as variants emerge across the globe and as we head into fall and winter, where we’ve experienced major spikes the last two years. CovGENE also holds promise in predicting long COVID, an elusive diagnosis the medical community is still trying to fully understand.

"Now that this unique approach has been validated, we look forward to its rapid development as a precision medicine tool that can improve the outcome of patients with COVID-19 and reduce the number of hospitalizations, especially the most vulnerable," said r. Peter Lipsky, AMPEL Chief Medical Officer, CEO and co-founder.

Related Links:
AMPEL BioSolutions 


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.